Efficacy of Lower Doses of Pioglitazone after Stroke or Transient Ischemic Attack In Patients with Insulin Resistance

CONCLUSIONS: Lower doses of pioglitazone appear to confer much of the benefit with less adverse effects than the full dose. Further study is needed to confirm these findings so that clinicians may optimize dosing of this secondary prevention strategy in stroke patients. This article is protected by copyright. All rights reserved.PMID:35253334 | DOI:10.1111/dom.14687
Source: Atherosclerosis - Category: Cardiology Authors: Source Type: research